APR-002 is under clinical development by Apros Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APR-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APR-002 overview
APR-002 is under development for the treatment of covid-19 disease. It is an enterohepatic-restricted TLR7 agonist, designed to act locally in the liver and thereby minimizing systemic immunotoxicity. It is administered through oral inhalation route. It was also under development for hepatitis B infections.
Apros Therapeutics overview
Apros Therapeutics is a drug discovery and development company focused on tissue-targeted small molecule innate immune agonists to increase tumor immunogenicity turning cold tumors hot. Apros Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of APR-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
